

**Supplemental information**

**Potent monoclonal antibodies neutralize**

**Omicron sublineages and other SARS-CoV-2 variants**





**Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, Yaroslav Tsybovsky, Kamille West, Celia Santos, Lisa F. Boyd, Hanh Nguyen, Anna Pomerence, Tyler Stephens, Adam S. Olin, Baoshan Zhang, Valeria De Giorgi, Michael R. Holbrook, Robin Gross, Elena Postnikova, Nicole L. Garza, Reed F. Johnson, David H. Margulies, Peter D. Kwong, Harvey J. Alter, Ursula J. Buchholz, Paolo Lusso, and Patrizia Farci**

**Cell Reports**


**Supplemental Information**

**Potent monoclonal antibodies neutralize  
Omicron sublineages and other SARS-CoV-2 variants**


Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, Yaroslav Tsybovsky, Kamille West,  
Celia Santos, Lisa F. Boyd, Hanh Nguyen, Anna Pomerence, Tyler Stephens,  
Adam S. Olia, Baoshan Zhang, Valeria De Giorgi, Michael R. Holbrook, Robin Gross,  
Elena Postnikova, Nicole L. Garza, Reed F. Johnson, David H. Margulies,  
Peter D. Kwong, Harvey J. Alter, Ursula J. Buchholz, Paolo Lusso, Patrizia Farci

<b>Single patient</b>		<b>Patient number</b>	<b>Neutralizing titer</b>	<b>Library size</b>	<b>Positive clones</b>	<b>Distinct clones</b>			
<b>Library 1</b>		1	80	$4.2 \times 10^7$	12	1			
									
<b>Library 2</b>		2	80	$4.0 \times 10^7$	70	3			
									
<b>Multiple patients</b>		<b>Patient number</b>	<b>Neutralizing titer</b>	<b>Library size</b>	<b>Positive clones</b>	<b>Distinct clones</b>			
<b>Library 3</b>		3	80	$9.1 \times 10^8$	300	9			
		4	80						
		5	320						
		6	320						
		7	320						
<b>Library 4</b>		8	160				$7.8 \times 10^8$	230	5
		9	160						
		10	640						
		11	160						
		12	640						

**Figure S1. Characteristics of 4 phage-display Fab libraries, related to Figure 1.** The libraries were generated from peripheral blood mononuclear cells (PBMC) obtained from convalescent COVID-19 donors, derived from either a single donor or five donors combined.



**Figure S2. Binding profiles of 12 Fabs to a stabilized trimeric SARS-CoV-2 spike protein (S-2P), related to Figure 1.** All the Fabs showed tight binding to the protein. The S-2P protein was coupled to the chip at a surface density 200-450 Rus. Fabs were flowed over the surface at graded concentrations ranging from 5.625 nM to 90 nM (color coded). Kinetic values were obtained using Biaeval 3.1; fits are indicated by the black lines.



**Figure S3. Binding of 12 Fabs derived from convalescent COVID-19 donors to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, related to Figure 2.** All of the Fabs shown, except one, are specific for the RBD, as demonstrated using the recombinant RBD protein as a competitor in ELISA. The red lines show the loss of signal when recombinant RBD was pre-incubated with the Fabs. Only one Fab, H11, was not inhibited, suggesting that its binding site is outside the RBD.


		Fab →										
		NE12	NF8	NG3	1G8	3B6	3F6	4B6	D12	NA8	NE8	2A12
IgG ↓	NE12	84	99	97	-31	90	30	58	58	62	85	82
	NF8	78	99	67	-17	94	16	75	97	85	98	86
	NG3	70	93	91	-64	93	57	98	84	72	82	75
	1G8	41	73	45	92	72	92	84	86	82	87	42
	3B6	55	87	61	-49	96	4	83	89	99	93	99
	3F6	27	33	24	64	16	86	27	34	47	22	18
	4B6	93	95	86	-38	98	5	80	87	81	97	78
	D12	81	93	83	-30	95	6	74	80	61	86	87
	NA8	69	88	65	-82	92	-18	37	63	51	74	76
	NE8	46	78	41	-60	78	-19	18	47	42	61	61
	2A12	68	88	70	-59	94	-15	28	66	64	84	86

**Figure S4. Cross-competition of 11 monoclonal antibodies for binding to the SARS-CoV-2 spike protein (S-2P) trimer, related to Figure 2.** To investigate if the epitopes recognized by the 11 monoclonal antibodies are distinct or overlapping, we performed cross-competition experiments between Fabs and complete IgG in ELISA. The percent competition was calculated using the following formula:  $[1 - (\text{average OD from wells containing test IgG with Fab} - \text{average OD from control wells}) / (\text{average OD from wells containing test IgG without Fab} - \text{average OD from control wells})] \times 100\%$ .


**A**

mAb	Live virus neutralization IC <sub>50</sub> (µg/ml)	
	WA-1	B.1.351 Beta
G6	>10	>10
4A12	>10	>10
4B7	>10	>10
A7	>10	>10
1B1	>10	>10
4C6	>10	>10
H11	>10	>10
1G8	3.969	0.298
3F6	3.150	0.221
3B6	0.020	>10
4B6	7.937	>10
D12	1.768	>10
NA8	0.442	0.039
2A12	0.039	>10
NE8	0.055	>10
NE12	0.028	>10
NF8	0.884	>10
NG3	0.055	>10
Lilly_CoV555	0.089	>10

>10	10-1	1-0.1	0.1-0.01	<0.01
-----	------	-------	----------	-------




**B**

**Figure S5. Live virus neutralization of WA-1 and B.1.351 SARS-CoV-2 strains by 18 monoclonal antibodies and correlation with pseudovirus neutralization, related to Figure 2. (A) Heat map of live virus neutralization against SARS-CoV-2 WA-1 and B.1.351. (B) Correlation between neutralizing activities of mAbs in the pseudovirus and live virus assays.**



**Figure S6. Cryo-EM data processing workflow leading to the structure of SARS-CoV-2 Spike in complex with Fab NE12, related to Figure 3. Software packages are indicated in square brackets.**




**A****B****C**

**Figure S7. Validation of the consensus cryo-EM map of SARS-CoV-2 spike in complex with Fab NE12, related to Figure 3.**




(A) Representative micrograph and 2D classes (insert).

(B) Fourier shell correlation (FSC) plots generated by Relion.

(C) Local resolution determined with ResMap.




**Figure S8. Cryo-EM data processing workflow leading to the structure of SARS-CoV-2 Spike in complex with Fab NA8, related to Figure 4. Software packages are indicated in square brackets.**

**A****B****C**

**Figure S9. Validation of the consensus cryo-EM map of SARS-CoV-2 spike in complex with Fab NA8, related to Figure 4.**

- (A) Representative micrograph and 2D classes (insert).  
 (B) Fourier shell correlation (FSC) plots generated by Relion.  
 (C) Local resolution determined with ResMap.




**Figure S10. Validation of the local cryo-EM structure of SARS-CoV-2 receptor binding domain (RBD) in complex with Fab NE12, related to Figure 3.**

(A) Fourier shell correlation (FSC) plots generated by Relion.

(B) FSC curve between the map and atomic model.

(C) Local resolution determined with ResMap.

(D) Examples of cryo-EM density.




**Figure S11. Validation of the local cryo-EM structure of SARS-CoV-2 receptor binding domain in complex with Fab NA8, related to Figure 4.**

(A) Fourier shell correlation (FSC) plots generated by Relion.

(B) FSC curve between the map and atomic model.

(C) Local resolution determined with ResMap.

(D) Examples of cryo-EM density.





**Figure S12. Comparison of binding modes and epitopes of RBD-directed antibodies NE12, Lilly\_CoV555 and REGN10933, related to Figure 5.**

(A) Cartoon representations of aligned RBD-Fab complexes for NE12 and Lilly\_CoV555 (from PDB 7I3n).

(B) The RBD is shown in surface representation with the epitopes of NE12 and Lilly\_CoV555 outlined with red and blue curves, respectively. Surface areas corresponding to the RBD residues forming the ACE-2 receptor interface are colored yellow.

(C) Cartoon representations of aligned RBD-Fab complexes for NE12 and REGN10933 (from PDB 6xdg).


(D) The RBD is shown in surface representation with the epitopes of NE12 and REGN10933 outlined with red and blue curves, respectively. Surface areas corresponding to the RBD residues forming the ACE-2 receptor interface are colored in yellow.

**A****B**

**Figure S13. Competition of various mAbs with S-6P trimer binding to ACE-2-positive cells, related to Figure 5.**

(A) Ability of monoclonal antibodies against the SARS-CoV-2 spike to block the interaction of the S-6P trimer to ACE2-expressing HEK293 cells. The trimer was directly labeled with phycoerythrin (PE) and pre-incubated with each of the mAbs or with PBS buffer (control) for 30 min before incubation with the cells for 30 min.

(B) Overlap between the NA8 epitope and the ACE2 footprint. The RBD is shown in surface representation. The epitope of NA8 is outlined with a red line. The ACE2 interface is colored in yellow.



**Figure S14. Plasma concentrations of anti-SARS-CoV-2 spike human antibodies in hamsters treated with mAbs NE12 and NA8, related to Figure 7.** Mean plasma levels of NE12 and NA8 in hamsters treated with the mAbs 24 hours after virus challenge with the original strain, WA-1, or the B.1.351 variant. The mAb concentrations were determined using a specific ELISA with the recombinant S-protein trimer (S-2P) immobilized on the plastic surface. The data represent mean values from 5 animals ( $\pm$  SEM).



**Table S1. Demographic characteristics and neutralizing antibody titers in 12 COVID-19 convalescent plasma donors, related to Figure 1**

<b>Patient number</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>
<b>Age</b>	65	60	53	35	49	40	66	62	58	52	54	61
<b>Gender</b>	F	F	M	M	M	M	F	M	F	F	M	F
<b>Neutralizing antibody titer</b>	80	80	80	80	320	320	320	160	160	640	160	640
<b>Blood collected (mL)</b>	40	35	19	24	24	40	22	28	38	40	32	18

**Table S2. Binding affinity of anti-SARS-CoV-2 Fabs to the S-2P trimer, as measured by surface plasmon resonance, related to Figure 1**

<b>Fab</b>	<b><math>K_D</math> (M)</b>	<b><math>k_d</math> (s<sup>-1</sup>)</b>	<b><math>k_a</math> (1/Ms)</b>
<b>1G8</b>	6.2e-10	2.0e-4	4.6e5
<b>3F6</b>	4.3e-10	8.2e-4	3.9e6
<b>4B6</b>	8.7e-10	1.1e-3	1.3e6
<b>D12</b>	7.2e-10	8.7e-4	1.3e6
<b>NA8</b>	4.6 e-10	1.2e-3	2.8e6
<b>2A12</b>	3.0e-10	8.0e-4	2.7e6
<b>NE8</b>	1.8e-10	5.7e-3	3.1e6
<b>NE12</b>	6.1e-10*	6.5e-4	1.3e6
<b>NG3</b>	2.2e-10	2.0e-4	1.0e6
<b>4B7</b>	1.1e-9	1.7e-3	1.6e6
<b>A7</b>	3.9e-10	7.8e-4	2.2e6
<b>H11</b>	6.5e-9	1.7e-3	2.7e5

\*Constants were determined using BiaEvaluation software. Constants are the average of two different analyses. Only one reliable data set was obtained for 4B7.

**Table S3. Genetic properties of 18 Fabs specific for the spike (S) protein of SARS-CoV-2, related to Figure 1**

Fab	Heavy chain						Light chain				
	VH	JH	DH	HCDR3	CDR3 length	VH SHM	VL	JL	LCDR3	CDR3 length	VL SHM
<b>G6</b>	1-24	5	6-13	CATAPAIAAAAYTGWFDPW	16	4	LV2-14	LJ2	CSSYAGSSVVF	9	9
<b>4A12</b>	3-9	6	2-15	CVRGEILGDDYYRMDVW	15	14	KV1-39	KJ4	CQQSYSTPLTF	9	0
<b>4B7</b>	3-30-3	4	1-26	CARPHSGSYFSHFYDW	14	8	KV3-20	KJ1	CQQYGSSPWTF	9	0
<b>A7</b>	1-69	6	3-10	CANGAHNWGSGFSYYSYMDVW	20	5	KV3-20	KJ4	CQQYGSSPLTF	9	0
<b>1B1</b>	1-69	6	4-17	CARYIPDFGDYVTPYYYYALDVW	21	15	KV1-39	KJ4	CQQSYSTPLTF	9	0
<b>4C6</b>	3-30	3	4-23	CARSYGGNYLSAFDVW	14	11	KV3-15	KJ3	CQQNNEWPLTF	9	9
<b>H11</b>	1-46	3	3-10	CVYDTGPHAFDIW	11	3	LV1-51	LJ3	CGTWDSLSLVWVF	11	2
<b>1G8</b>	1-2	6	D1-7	CARDRKFDNSWNKYDKGRYGMDVW	21	12	KV1-39	KJ4	CQQSYTLTF	7	6
<b>3F6</b>	1-2	4	3-22	CARVPRNYDRRGLVYEDYFEYW	22	8	KV3-20	KJ2	CQQFGSPPIF	9	6
<b>3B6</b>	3-23	4	3-22	CAKVGRRSNTLIVVATEFDYW	19	14	KV1-39	KJ3	CQQGYSTPPLTF	11	6
<b>4B6</b>	1-69	6	4-11	CARDSTESPLYGMDVW	14	8	KV1-39	KJ2	CQQSYSTPLTF	9	0
<b>D12</b>	3-13	3	3-16	CARGGPLGGGEDAFDMW	15	9	KV1-5	KJ2	CQHYSGYPTYF	9	16
<b>NA8</b>	3-33	3	2-8	CARDPHCTGGVCDAFDLW	16	15	KV1-39	KJ2	CQQSYSTPYTF	9	1
<b>2A12</b>	1-2	4	3-22	CARTLYYYDSSGNLSLDHW	17	7	KV1-39	KJ3	CQQSYSSQWTF	9	24
<b>NE8</b>	1-69	4	2-15	CARGHRYCSGGSCFPYFDYW	18	5	KV1-39	KJ2	CQQSYSTPRTF	9	0
<b>NE12</b>	1-2	6	1-26	CAREETIVGATPPYGLDVW	17	6	KV3-11	KJ5	CQQRSNWPPVTF	10	1
<b>NF8</b>	1-69	4	3-16	CAGVEAYHDSIWGTFAPRYFFGSW	22	14	KV1-39	KJ3	CQQSYSSPPTF	9	0
<b>NG3</b>	1-69	4	5-18	CARVSGYSFGPYFDYW	14	6	KV3-11	KJ3	CQQRSSWPPTF	9	0

**Table S4. Cryo-EM data collection and analysis statistics, related to Figures 3 and 4**

	S-6P in complex with Fab NE12		S-6P in complex with Fab NA8	
<b>Data collection and processing</b>				
Magnification	105,000		105,000	
Voltage (kV)	300		300	
Electron exposure (e <sup>-</sup> /Å <sup>2</sup> )	40		40	
Defocus range (μm)	-1.0 to -2.5		-1.0 to -2.5	
Pixel size (Å)	0.873		0.873	
Symmetry imposed	C1		C1	
Initial particle images (no.)	2,253,882		2,870,476	
Final particle images (no.)	201,607		454,910	
	Consensus map EMDB-26401	Local map EMDB-26402 PDB 7U9O	Consensus map EMDB-26403	Local map EMDB-26404 PDB 7U9P
Map resolution (Å)	3.1	3.4	2.9	3.5
FSC threshold	0.143		0.143	
Map resolution range (Å)	1.9-6.8	3.1-6.8	1.9-8.0	3.1-6.8
<b>Refinement</b>				
Initial model used (PDB code)		6xlu		6xlu
Model resolution (Å)		3.4		3.5
FSC threshold		0.5		0.5
Map sharpening <i>B</i> factor (Å <sup>2</sup> )	-44.4	-125.7	-53.3	-165.1
Model composition				
Non-hydrogen atoms		6563		6126
Protein residues		829		777
Ligands (glycans)		3		4
Water		0		0
<i>B</i> factors (Å <sup>2</sup> ) (mean)				
Protein		58.9		65.8
Ligand		82.1		103.7
Water		N/A		N/A
R.m.s. deviations				
Bond lengths (Å)		0.007		0.013
Bond angles (°)		0.926		1.19
Validation				
MolProbity score		1.44		1.63
Clash score		1.55		2.49
Poor rotamers (%)		0.28		0.15
Ramachandran plot				
Favored (%)		90.34		88.16
Allowed (%)		9.53		11.57
Disallowed (%)		0.13		0.27